BIBR1591 INDUCES APOPTOSIS IN BREAST CANCER CELL LINE AND INCREASES EXPRESSION OF DAPK1, AND NR4A3.

Abstract

Background: Breast cancer, the world's most prevalent cancerous disease that threatens women, is mainly dependent upon ovarian endocrine secretion for its growth and development. Telomerase inhibitors have been widely studied for their use to treat various tumors. BIBR1591 is the first highly effective small molecule telomerase inhibitor that could inhibit telomerase of many types of cancer cells at sub micromolar concentration Aim: Our research aimed to study the molecular mechanism and action of BIBR1591, trying to understand the telomerase inhibitor in breast cancer, focusing on its ability to induce apoptosis and alter the expression of specific genes.

Material and methods: The MCF-7 breast cancer cell line was treated with BIBR1591 at different concentrations for 48 hours, and the effects on cell viability and apoptosis were evaluated using MTT and flow cytometry assays, respectively. The DAPK1, and NR4A3 gene expression levels were assessed by qPCR.

Results: Treatment with BIBR1591 resulted in a dose-dependent decrease in cell viability and a significant increase in apoptosis in the MCF-7 cells. Furthermore, the expression levels of CDH13, DAPK1, and NR4A3 genes were upregulated following treatment with BIBR1591.

Conclusion: Our research concludes that BIBR1591 has unique molecular anticancer effect as its expression of CDH13, DAPK1, and NR4A3 genes. These results support the potential use of BIBR1591 as a therapeutic option for breast cancer treatment.